Day One Biopharmaceuticals Dirección
Dirección controles de criterios 3/4
El CEO de Day One Biopharmaceuticals' es Jeremy Bender , nombrado en Sep 2020, tiene una permanencia de 3.58 años. compensación anual total es $6.91M, compuesta por 9.4% salario y 90.6% primas, incluidas acciones y opciones de la empresa. posee directamente un 2.02% de las acciones de la empresa, por valor de $23.32M. La antigüedad media del equipo directivo y de la junta directiva es de 2.6 años y 3.1 años, respectivamente.
Información clave
Jeremy Bender
Chief Executive Officer (CEO)
US$6.9m
Compensación total
| Porcentaje del salario del CEO | 9.4% |
| Permanencia del CEO | 3.7yrs |
| Participación del CEO | 1.9% |
| Permanencia media de la dirección | 2.7yrs |
| Promedio de permanencia en la Junta Directiva | 3.2yrs |
Actualizaciones recientes de la dirección
Recent updates
Day One Pharmaceuticals: Ojemda Approval A Big Win, Current Valuation Fair
Apr 24We're Hopeful That Day One Biopharmaceuticals (NASDAQ:DAWN) Will Use Its Cash Wisely
Mar 18
Navigating Day One Biopharmaceuticals' Financial Health And Clinical Prospects
Feb 01We're Hopeful That Day One Biopharmaceuticals (NASDAQ:DAWN) Will Use Its Cash Wisely
Dec 04We're Not Very Worried About Day One Biopharmaceuticals' (NASDAQ:DAWN) Cash Burn Rate
Jun 19We're Hopeful That Day One Biopharmaceuticals (NASDAQ:DAWN) Will Use Its Cash Wisely
Mar 08Here's Why We're Not Too Worried About Day One Biopharmaceuticals' (NASDAQ:DAWN) Cash Burn Situation
Nov 22Day One Biopharmaceuticals: Recent Strong Data, And Major Catalysts Ahead
Sep 04Day One Biopharmaceuticals GAAP EPS of -$0.60
Aug 04Day One Biopharmaceuticals, Inc.'s (NASDAQ:DAWN) Intrinsic Value Is Potentially 52% Above Its Share Price
Jun 18Day One Biopharmaceuticals: Early Pediatric Brain Cancer Data Makes Tentative Buy Case
Jun 15We're Not Very Worried About Day One Biopharmaceuticals' (NASDAQ:DAWN) Cash Burn Rate
Apr 29An Intrinsic Calculation For Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Suggests It's 42% Undervalued
Jan 14Day One Biopharmaceuticals (NASDAQ:DAWN) Is In A Good Position To Deliver On Growth Plans
Dec 10Day One Biopharmaceuticals (NASDAQ:DAWN) Is In A Good Position To Deliver On Growth Plans
Aug 27Day One Biopharma draws bullish calls as quiet period ends
Jun 21Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | -US$209m |
| Dec 31 2023 | US$7m | US$647k | -US$189m |
| Sep 30 2023 | n/a | n/a | -US$175m |
| Jun 30 2023 | n/a | n/a | -US$166m |
| Mar 31 2023 | n/a | n/a | -US$157m |
| Dec 31 2022 | US$5m | US$610k | -US$142m |
| Sep 30 2022 | n/a | n/a | -US$124m |
| Jun 30 2022 | n/a | n/a | -US$105m |
| Mar 31 2022 | n/a | n/a | -US$183m |
| Dec 31 2021 | US$20m | US$523k | -US$171m |
| Sep 30 2021 | n/a | n/a | -US$183m |
| Jun 30 2021 | n/a | n/a | -US$167m |
| Mar 31 2021 | n/a | n/a | -US$54m |
| Dec 31 2020 | US$3m | US$142k | -US$41m |
Compensación vs. Mercado: La compensación total ($USD6.91M) de Jeremy está en línea con el promedio de empresas de tamaño similar en el mercado US ($USD5.58M).
Compensación vs. Ingresos: La compensación de Jeremy ha aumentado mientras la empresa no es rentable.
CEO
Jeremy Bender (52 yo)
3.7yrs
Permanencia
US$6,913,959
Compensación
Dr. Jeremy Bender, Ph D., M.B.A. serves as Chief Executive Officer, President and Director of Day One Biopharmaceuticals, Inc. since September 2020. He serves as President, Chief Executive Officer and Dire...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| CEO, President & Director | 3.7yrs | US$6.91m | 1.93% $ 27.7m | |
| Co-Founder and Head of R&D | 6.3yrs | US$2.49m | 2.49% $ 35.7m | |
| COO, CFO & Secretary | 3.3yrs | US$3.55m | 0.25% $ 3.6m | |
| General Counsel and Chief Compliance Officer | 1.6yrs | US$2.77m | 0.019% $ 272.4k | |
| Chief of Technology Operations | no data | sin datos | sin datos | |
| Chief People Officer | 2.7yrs | sin datos | sin datos | |
| Chief Development Officer | no data | sin datos | sin datos | |
| Chief Commercial Officer | 1.3yrs | sin datos | sin datos | |
| Chief Medical Officer | less than a year | sin datos | sin datos |
2.7yrs
Permanencia media
52yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de DAWN se considera experimentado (2.6 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| CEO, President & Director | 3.7yrs | US$6.91m | 1.93% $ 27.7m | |
| Independent Director | 3.7yrs | US$350.75k | 0.083% $ 1.2m | |
| Board Observer | no data | sin datos | sin datos | |
| Chairman of the Board & Lead Independent Director | 1.7yrs | US$383.38k | 0% $ 0 | |
| Board Observer | no data | sin datos | sin datos | |
| Independent Director | less than a year | sin datos | 0% $ 0 | |
| Independent Director | 2.8yrs | US$342.88k | 0% $ 0 | |
| Independent Director | 4.4yrs | US$342.88k | 0% $ 0 | |
| Independent Director | 3.2yrs | US$351.75k | 0.058% $ 829.0k | |
| Independent Director | 3.3yrs | US$352.50k | 0.066% $ 941.0k | |
| Independent Director | 4.4yrs | US$340.75k | 0.0057% $ 82.1k | |
| Independent Director | less than a year | sin datos | 0% $ 0 |
3.2yrs
Permanencia media
53yo
Promedio de edad
Junta con experiencia: La junta directiva de DAWN se considera experimentada (3.1 años de antigüedad promedio).